DK1611890T3 - Fremgangsmåde til evaluering og behandling af cancer - Google Patents
Fremgangsmåde til evaluering og behandling af cancerInfo
- Publication number
- DK1611890T3 DK1611890T3 DK05254157T DK05254157T DK1611890T3 DK 1611890 T3 DK1611890 T3 DK 1611890T3 DK 05254157 T DK05254157 T DK 05254157T DK 05254157 T DK05254157 T DK 05254157T DK 1611890 T3 DK1611890 T3 DK 1611890T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- evaluation
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000011156 evaluation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/883,436 US20050003422A1 (en) | 2003-07-01 | 2004-07-01 | Methods for assessing and treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1611890T3 true DK1611890T3 (da) | 2009-11-16 |
Family
ID=35058443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05254157T DK1611890T3 (da) | 2004-07-01 | 2005-07-01 | Fremgangsmåde til evaluering og behandling af cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050003422A1 (da) |
EP (1) | EP1611890B1 (da) |
JP (1) | JP2006014739A (da) |
KR (1) | KR20060048684A (da) |
CN (1) | CN1721553A (da) |
AR (1) | AR049564A1 (da) |
AT (1) | ATE440604T1 (da) |
AU (1) | AU2005202520A1 (da) |
BR (1) | BRPI0502433A (da) |
CA (1) | CA2512493A1 (da) |
DE (1) | DE602005016189D1 (da) |
DK (1) | DK1611890T3 (da) |
MX (1) | MXPA05007207A (da) |
PT (1) | PT1611890E (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0503418A (pt) * | 2004-05-06 | 2006-04-11 | Johnson & Johnson | prognóstico para malignidade hematológica |
US20080090242A1 (en) * | 2006-09-29 | 2008-04-17 | Schering Corporation | Panel of biomarkers for prediction of fti efficacy |
EP2135073A4 (en) * | 2007-03-12 | 2011-09-21 | Veridex Llc | METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
CA2659638C (en) * | 2008-03-21 | 2013-07-23 | Mission Itech Hockey Ltd. | Helmet for a hockey or lacrosse player |
IL289062B2 (en) * | 2009-02-11 | 2024-12-01 | Caris Mpi Inc | Molecular profiling of tumors |
US11559540B2 (en) | 2010-07-28 | 2023-01-24 | Janssen Pharmaceutica Nv | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
EP3489680B1 (en) * | 2010-07-28 | 2024-07-03 | Janssen Pharmaceutica NV | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
WO2017184968A1 (en) * | 2016-04-22 | 2017-10-26 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
AU2018313738B2 (en) * | 2017-08-07 | 2024-07-04 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
US10806730B2 (en) | 2017-08-07 | 2020-10-20 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
US20210231666A1 (en) * | 2018-06-06 | 2021-07-29 | La Jolla Institute For Immunology | Cd33 monocytes as a biomarker |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221605A (en) | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
SI0865440T1 (en) | 1995-12-08 | 2002-08-31 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
DE69725604T2 (de) | 1996-12-20 | 2005-03-03 | Sergazy Mynzhasarovich Adekenov | VERFAHREN UND GERÄT ZUR HERSTELLUNG VPM LYOPHILISIERTEM 1ß, 10ß-EPOXY-13-DIMETHYLAMINO-GUAIA-3(4)-EN-6,12-OLID-HYDROCHLORID |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
JP2005522990A (ja) * | 2001-10-30 | 2005-08-04 | オルソ−クリニカル ダイアグノスティクス,インコーポレイティド | 白血病の評価及び処理方法 |
US7473526B2 (en) * | 2002-03-29 | 2009-01-06 | Veridex, Llc | Breast cancer prognostic portfolio |
US20030224422A1 (en) * | 2002-04-08 | 2003-12-04 | St. Jude Children's Research Hospital, Inc. | Pre-and post therapy gene expression profiling to identify drug targets |
EP1502962A3 (en) * | 2003-07-01 | 2006-01-11 | Veridex, LLC | Methods for assessing and treating cancer |
-
2004
- 2004-07-01 US US10/883,436 patent/US20050003422A1/en not_active Abandoned
-
2005
- 2005-06-09 AU AU2005202520A patent/AU2005202520A1/en not_active Abandoned
- 2005-06-23 CA CA002512493A patent/CA2512493A1/en not_active Abandoned
- 2005-06-29 KR KR1020050056876A patent/KR20060048684A/ko not_active Withdrawn
- 2005-06-30 MX MXPA05007207A patent/MXPA05007207A/es unknown
- 2005-06-30 JP JP2005192550A patent/JP2006014739A/ja not_active Abandoned
- 2005-06-30 AR ARP050102730A patent/AR049564A1/es unknown
- 2005-07-01 DK DK05254157T patent/DK1611890T3/da active
- 2005-07-01 EP EP05254157A patent/EP1611890B1/en not_active Not-in-force
- 2005-07-01 PT PT05254157T patent/PT1611890E/pt unknown
- 2005-07-01 BR BRPI0502433-1A patent/BRPI0502433A/pt not_active IP Right Cessation
- 2005-07-01 DE DE602005016189T patent/DE602005016189D1/de active Active
- 2005-07-01 CN CNA2005100822115A patent/CN1721553A/zh active Pending
- 2005-07-01 AT AT05254157T patent/ATE440604T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2512493A1 (en) | 2006-01-01 |
CN1721553A (zh) | 2006-01-18 |
JP2006014739A (ja) | 2006-01-19 |
AR049564A1 (es) | 2006-08-16 |
DE602005016189D1 (de) | 2009-10-08 |
ATE440604T1 (de) | 2009-09-15 |
PT1611890E (pt) | 2009-09-29 |
US20050003422A1 (en) | 2005-01-06 |
BRPI0502433A (pt) | 2006-04-04 |
EP1611890B1 (en) | 2009-08-26 |
EP1611890A1 (en) | 2006-01-04 |
KR20060048684A (ko) | 2006-05-18 |
AU2005202520A1 (en) | 2006-01-19 |
MXPA05007207A (es) | 2006-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1830838T3 (da) | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
IS8204A (is) | Tæki og aðferð til að hluta niður | |
DK2878297T3 (da) | Lægemidler til behandling og forebyggelse af fibrotiske sygdomme | |
DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
DK1791791T3 (da) | Fremgangsmåder og sammensætninger til behandling af vand | |
DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
DK1706112T3 (da) | Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom | |
DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
DK1891571T3 (da) | Hæmning af spredning af uønskede koder og data | |
DK1725253T3 (da) | Medikamenter og fremgangsmåder til behandling af hovedpine | |
DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
DK1628530T3 (da) | Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis | |
NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
DK2030476T3 (da) | Fremgangsmåde og system til forbedring af forståeligheden af lyde | |
DK1948852T3 (da) | Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden | |
DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
IS8597A (is) | Samsetningar rísedrónats og aðferðir við notkun þess | |
DK1919290T3 (da) | Fremgangsmåder og produkter til behandling af sygdomme | |
DK2037766T3 (da) | Fremgangsmåde og system til forbedret anvendelse af akutiske bølger med høj intensitet | |
DK1851340T3 (da) | Fremgangsmåde til diagnosticering og behandling af cancer ved anvendelse af b-catenin-splejsningsvarianter | |
DE602006007889D1 (de) | Belichtungsverfahren und -vorrichtung | |
DK1599469T3 (da) | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed |